German drugmaker Bayer (BAYN: DE) has renewed its partnership with China’s Tsinghua University for another three years, reinforcing its strategy to develop treatments aligned with China’s growing role in global biopharma R&D.
The deal, which builds on a collaboration that began in 2009, aims to accelerate early-stage research in oncology, cardiovascular and renal diseases, neurology, immunology, and rare conditions. Bayer will continue to fund research projects and provide support for scientists based at the university, located in Beijing.
More than 70 joint research efforts and over 10 academic publications have emerged from the alliance so far. The collaboration also includes the Bayer Microfunding program, launched in 2022, which has backed nine projects focused on translating scientific advances into potential therapies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze